SOMERSET, N.J. - In a significant development for patients suffering from relapsed or refractory multiple myeloma, CARVYKTI (ciltacabtagene autoleucel) has received a positive recommendation from the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC). This recommendation highlights CARVYKTI’s efficacy and safety profile, paving the way for earlier treatment options for these patients.
Legend Biotech Corporation (NASDAQ: LEGN), a leading global cell therapy company, made the announcement today. CARVYKTI, also known as cilta-cel, is being considered for adult patients who have relapsed or refractory multiple myeloma and have previously received at least one line of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IM).
Multiple myeloma is a complex and incurable hematological malignancy characterized by the proliferation of abnormal plasma cells in the bone marrow. Although significant progress has been made in its treatment over the years, relapses or refractory cases remain a challenge. CARVYKTI brings hope for these patients by potentially offering an effective therapy that targets their specific needs.
The positive recommendation from ODAC is based on the data obtained from an open-label multicenter clinical trial known as CARTITUDE-1. This trial evaluated the safety and efficacy of CARVYKTI in relapsed or refractory multiple myeloma patients who had received prior PI and IM therapies. The results demonstrated promising outcomes, including high response rates and durable remissions.
CARVYKTI is a chimeric antigen receptor (CAR) T-cell therapy. It works by genetically engineering a patient’s own T-cells to express a CAR, which can recognize and target BCMA (B-cell maturation antigen), a protein overexpressed in multiple myeloma cells. When infused back into the patient’s body, these CAR T-cells seek out and destroy the BCMA-expressing cancer cells.
The FDA’s ODAC recognized the potential of CARVYKTI as an innovative and groundbreaking therapy for patients with relapsed or refractory multiple myeloma during their deliberations. They considered various factors, including the unmet medical need, the clinical trial data, and the overall benefit-risk assessment. The committee’s recommendation will undergo further review by the FDA for final approval, which, if granted, would provide a valuable treatment option for patients in urgent need.
With the increasing recognition of the efficacy and safety of CARVYKTI, patients with relapsed or refractory multiple myeloma may soon have access to a potentially life-saving therapy. This milestone represents a step forward in the field of cell therapy and brings hope for improving the outcomes of patients battling this devastating disease.
Comments